Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
This research is being done to find out how safe and how well the combination of lapatinib and vorinostat works against advanced cancers.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Pilot and Phase II- Vorinostat and Lapatinib in Patients With Advanced Solid Tumor Malignancies and Women With Recurrent Local-Regional or Metastatic Breast Cancer to Evaluate Response and Biomarkers of EMT and Breast Cancer Stem Cells|
- Clinical benefit rate (Complete Response (CR), Partial Response (PR), and Stable Disease (SD) ≥ 6 months) of vorinostat in combination with lapatinib in patients with locally recurrent or metastatic breast cancer. [ Time Frame: Radiological evaluations are performed every 12 weeks to determine disease status ] [ Designated as safety issue: No ]
- Progression free survival (PFS) of vorinostat in combination with lapatinib in patients with locally recurrent or metastatic breast cancer. [ Time Frame: Radiological evaluations are performed every 12 weeks to determine disease status ] [ Designated as safety issue: No ]
|Study Start Date:||March 2010|
|Estimated Study Completion Date:||December 2014|
|Estimated Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
|Experimental: Vorinostat and Lapatinib||
300 mg 4 days on then 3 days off
As defined in the protocol, the dose of vorinostat may be increased to 400 mg 4 days on then 3 days off if the adverse event threshold has not been met.
Other Name: ZolinzaDrug: Lapatinib
1,250 mg once daily
Other Name: Tykerb
Lapatinib is an anti-cancer drug that is approved by the Food and Drug Administration (FDA) for the treatment of metastatic HER2-positive breast cancer. HER2 is a protein involved in the growth of some cancer cells. In lab tests and small clinical studies, lapatinib is also found to kill other types of cancer that have another related protein called epidermal growth factor receptor (EGFR). For participants who have other cancers, the use of lapatinib in this study is investigational. This means the drug is not FDA approved for this use.
Vorinostat is only FDA approved for the treatment of cutaneous T cell lymphoma (a type of cancer). Vorinostat is not currently FDA approved for breast cancer or any other type of cancer. The use of vorinostat in this study is investigational.
Cancer cells can travel through the blood stream and spread to other organs. This process is called metastasis. Lab tests and small clinical trials have shown that vorinostat kills some cancer cells and prevents these cancer cells from traveling through the blood stream. These trials have shown that vorinostat improves how well lapatinib kills cancer cells.
Newer studies have also shown that a subset of cells, called "cancer stem cells," can come back, spread, and become resistant to the usual chemotherapy. In laboratory tests, we found that vorinostat and lapatinib can reduce the number of cancer stem cells. We are looking at combining vorinostat and lapatinib in the hope that we can reduce the number of cancer stem cells and cancer cells traveling through the blood stream.
There are two parts to this study.
First part- We want to learn more about the best dose of vorinostat to be given with lapatinib. We want to learn about how much vorinostat and lapatinib goes into the blood during treatment. We also want to learn the side effects (safety) of the combination of vorinostat and lapatinib. All patients will receive the FDA-approved dose of lapatinib. The first group of patients will get a slightly lower dose of vorinostat than is given normally. If the side effects are not too serious, the next group of patients will get the dose of vorinostat that is given normally.
Second part- We will find out how well the combination of vorinostat and lapatinib works in patients with HER2-positive metastatic breast cancer.
|Contact: Nancy Taitfirstname.lastname@example.org|
|Contact: Jane Lewisemail@example.com|
|United States, Maryland|
|University of Maryland Greenebaum Cancer Center||Recruiting|
|Baltimore, Maryland, United States, 21201|
|Principal Investigator: Saranya Chumsri, MD|
|Principal Investigator:||Saranya Chumsri, MD||University of Maryland|